There is a need to identify new therapeutics for the treatment of serious infections and cancer. Given an increasing population of immunocompromised individuals, in particular those undergoing treatment for cancer, fungal and bacterial infections lead to debilitative illnesses and these patients have a high mortality rate. A substantial amount of work has been done to characterize an antifungal we named occidiofungin. Current studies support investigational studies aimed at determining occidiofungin's therapeutic potential for the treatment of fungal infections and cancer. A detailed structural analysis, spectrum of activity, and animal toxicity studies have been performed on occidiofungin. From these studies, occidiofungin has been determined to be rapidly fungicidal at submicromolar concentrations and has a broader spectrum of activity than other clinically used antifungals. Furthermore, compared to antifungals used to treat serious fungal infections, occidiofungin appears to have less of a toxicological effect in an animal study compared to clinically approved antifungal agents. Occidiofungin has also demonstrated to inhibit the growth of cancer cells at nanomolar concentrations. Given that occidiofungin has demonstrated properties superior to currently used antifungal and anticancer agents, continued development of occidiofungin for clinical use is warranted. Occidiofungin holds great promise for the treatment of fungal and cancer diseases.
Antimicrobial and Anticancer Discovery
Sano chemicals is actively identifying novel agents that can be screened for potential applications in treating or preventing infectious diseases, cancer, or biofouling. The company has an interested in licensing opportunities of other isolated antimicrobial compounds.